Articel in BioStock: CombiGene raised 75MSEK through rights issue
This week, CombiGene announced the outcome of a rights issue, which was was resolved by the board of directors on 8 March 2021 based on the authorisation from the annual general meeting held on 29 June 2020. CombiGene will receive proceeds of approximately 75 MSEK before issue costs, which means that the company can advance its preclinical program for CG01 and in vivo studies in the lipodystrophy project CGT2.
CEO Jan Nilsson joined BioStock for a comment on the financing round.
Read more >>
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.